🇺🇸 FDA
Patent

US 8304422

Compositions and methods for inhibition of the JAK pathway

granted A61PA61P37/00A61P37/06

Quick answer

US patent 8304422 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P37/00, A61P37/06